MedTrace Logo

Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP Study)

NCT02003261 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2019-08-21

No results posted yet for this study

Summary

This study is to examine the superiority of the combined treatments of transdiagnostic cognitive-behavior therapy (Unified Protocol; UP) and Treatment-As-Usual in comparison with the waiting-list with Treatment-As-Usual in the reduction of depressive and anxiety symptoms among depressive and anxiety disorders.

Conditions

  • Anxiety Disorders
  • Depressive Disorders

Interventions

BEHAVIORAL

Unified Protocol with Treatment As Usual

Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university. UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure.

OTHER

Treatment As Usual

Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.

Sponsors & Collaborators

  • National Center of Neurology and Psychiatry, Japan

    lead OTHER

Principal Investigators

  • Masaya Ito, Ph.D. · National Center for Cognitive-Behavior Therapy and Research, National Center of Neurology and Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2018-11-02
Completion
2019-04-05

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02003261 on ClinicalTrials.gov